var data={"title":"Mometasone (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mometasone (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390073?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mometasone-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mometasone (topical): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=mometasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mometasone (topical): Pediatric drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775141\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elocon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775142\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Elocom</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775150\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775297\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical: Apply sparingly, do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cream, ointment:</i> Apply a thin film to affected area once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lotion, solution:</i> Apply a few drops to affected area once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775296\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mometasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mometasone (topical): Pediatric drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Corticosteroid-responsive dermatoses:</b> Topical: Apply sparingly, do not use occlusive dressings. Therapy should be discontinued when control is achieved; consider reassessment of diagnosis if no improvement is seen within 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cream, ointment:</i> Children &ge;2 years and Adolescents: Refer to adult dosing. Do not use in pediatric patients for longer than 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Lotion, solution:</i> Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775298\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution as elderly patients may be more susceptible to systemic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25944040\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25944041\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775347\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elocon: 0.1% (15 g, 45 g, 50 g) [contains soybean lecithin]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elocon: 0.1% (30 mL [DSC], 60 mL [DSC]) [contains isopropyl alcohol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elocon: 0.1% (15 g, 45 g) [contains propylene glycol stearate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (15 g, 45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1% (30 mL, 60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775144\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775300\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Apply sparingly. Avoid mucous membranes; manufacturer labeling recommends avoiding application to the eyes, face, underarms, and groin (including diaper area). Do not wrap, cover, or bandage affected area.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, ointment: Apply thin film to affected area.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lotion, solution: Apply a few drops to affected area and massage lightly until medication disappears.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775230\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Corticosteroid-responsive dermatoses:</b> Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775128\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elocon lotion may be confused with ophthalmic solutions. Manufacturer's labeling emphasizes the product is <b>NOT</b> for use in the eyes.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775239\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Tingling of skin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Bacterial skin infection, burning sensation of skin, furunculosis, pruritus, skin atrophy, stinging of skin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acne rosacea, candidiasis, decreased cortisol (pediatric patients), folliculitis, paresthesia, skin depigmentation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775236\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed within the manufacturer&rsquo;s US product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to mometasone furoate, other corticosteroids, or any component of the formulation; viral (eg, herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations, acne vulgaris, rosacea, pruritus without inflammation; ophthalmic use; use with occlusive dressings</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775237\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;Contact dermatitis: Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation; discontinue use if irritation occurs and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not for treatment of diaper dermatitis. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775244\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775245\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9782&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775231\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775232\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses. Use of mild to moderate potency topical corticosteroids is preferred in pregnant females and the use of large amounts or use for prolonged periods of time should be avoided (Chi 2016; Chi 2017; Murase 2014). Also avoid areas of high percutaneous absorption (Chi 2017). The risk of stretch marks may be increased with use of topical corticosteroids (Murase 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775235\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sufficient quantities of mometasone are absorbed following topical administration to produce detectable amounts in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Systemic corticosteroids are present in breast milk. Although the manufacturer recommends that caution be used, topical corticosteroids are generally considered acceptable for use in breastfeeding females (Butler 2014; WHO 2002). Do not apply topical corticosteroids to breast until breastfeeding ceases (Leachman 2006); hypertension was noted in a breastfed infant when a high potency topical corticosteroid was applied to the nipple (Butler 2014; Leachman 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775251\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Mometasone has intermediate range potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775253\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Absorption: Cream: 0.4% (increased by inflammation); Lotion, ointment, solution: 0.7% (increased by inflammation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775349\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Elocon External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $69.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Mometasone Furoate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $26.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Elocon External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $69.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Mometasone Furoate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (15 g): $24.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mometasone Furoate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (30 mL): $29.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961989\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avocom (KW);</li>\n      <li>Cortimon (BD);</li>\n      <li>Dermacortine (PE);</li>\n      <li>Dermome (TW);</li>\n      <li>Dermotasone (KR);</li>\n      <li>Dermovel (ID);</li>\n      <li>Ecural (DE);</li>\n      <li>Eczaderm (KW, SA);</li>\n      <li>Elica (AE, BH, ES, JO, KW, LB, PH, QA, SA);</li>\n      <li>Elicort (PH);</li>\n      <li>Elisone (HK);</li>\n      <li>Elna (ET);</li>\n      <li>Elocom (AE, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CO, CR, CZ, DO, EG, ES, ET, GH, GM, GN, GT, HN, HR, IL, IQ, IR, JO, KE, KR, KW, LB, LR, LU, LV, LY, MA, ML, MR, MU, MW, NE, NG, NI, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SC, SD, SI, SK, SL, SN, SV, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Elocon (AR, AT, BB, CY, DK, EE, FI, GB, GR, ID, IE, IN, IS, IT, LT, LV, MT, NL, NO, PH, PY, SE, TR, UY, VE);</li>\n      <li>Elocon Cream (AU, NZ);</li>\n      <li>Elocon Ointment (AU, NZ);</li>\n      <li>Elokom (UA);</li>\n      <li>Elomet (EC, HK, LK, MY, SG, TH, TW, VN);</li>\n      <li>Eloson (CN);</li>\n      <li>Elosone (ET, HK, LK, SG);</li>\n      <li>Elozon (UA);</li>\n      <li>Flogocort (EC);</li>\n      <li>Inpura (KR);</li>\n      <li>Intercon (ID);</li>\n      <li>Konex (ES);</li>\n      <li>Lavelia Lotion (KR);</li>\n      <li>Loksin (ID);</li>\n      <li>Lomeane (PH);</li>\n      <li>Mefurosan (ID);</li>\n      <li>Melocon (ID);</li>\n      <li>Meloderm (BD);</li>\n      <li>Melomet (MY);</li>\n      <li>Metaz (AE, JO, KW, QA);</li>\n      <li>Mezo (PH);</li>\n      <li>Mofulex (ID);</li>\n      <li>Mofuroate (TW);</li>\n      <li>Momate (PH, TH);</li>\n      <li>Momecort (PH);</li>\n      <li>Momed (EC);</li>\n      <li>Momet (ID);</li>\n      <li>Momezon (UA);</li>\n      <li>Monovel (AE, BH, CO, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Moricort (KR);</li>\n      <li>Mosone (PH);</li>\n      <li>Motaderm (ID);</li>\n      <li>Moteson (ID);</li>\n      <li>Mtaz (LK);</li>\n      <li>Novasone Cream (AU);</li>\n      <li>Novasone Lotion (AU);</li>\n      <li>Novasone Ointment (AU);</li>\n      <li>Soneta (BD);</li>\n      <li>Suqi (CN);</li>\n      <li>Topcort (HK);</li>\n      <li>Vizomet (HK, MY, SG);</li>\n      <li>Zatamil (AU, HK);</li>\n      <li>Zynovate (ET, JO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/28233354/pubmed\" target=\"_blank\" id=\"28233354\">28233354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi CC, Wang SH, Kirtschig G. Safety of topical corticosteroids in pregnancy. <i>JAMA Dermatol</i>. 2016;152(8):934-935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/27366995/pubmed\" target=\"_blank\" id=\"27366995\">27366995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elocom (mometasone furoate) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elocon cream (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elocon lotion (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elocon ointment (mometasone furoate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mometasone furoate solution [prescribing information]. Melville, NY: E. Fougera &amp; Co; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mometasone-topical-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9782 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8775141\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8775142\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8775150\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8775297\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8775296\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8775298\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25944040\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25944041\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8775347\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8775144\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8775300\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8775230\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8775128\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8775239\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8775236\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8775237\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8775244\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8775245\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8775231\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8775232\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8775235\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8775251\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8775253\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8775349\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961989\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9782|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mometasone-topical-patient-drug-information\" class=\"drug drug_patient\">Mometasone (topical): Patient drug information \t</a></li><li><a href=\"topic.htm?path=mometasone-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Mometasone (topical): Pediatric drug information \t</a></li></ul></div></div>","javascript":null}